Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Cardiol Therapeutics Inc
CRDL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.16
0.006
0.52%
Últ. Act.: Oct 20, 6:39 PM
$1.16
0.006
0.52%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Opciones
Informe de acciones
Privacy Manager
Cardiol Therapeutics Financials
Cardiol Therapeutics (CRDL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last
Benzinga Newsdesk
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
PRO
Cardiol Therapeutics Q4 EPS $(0.09) Beats $(0.12) Estimate
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from
Benzinga Newsdesk
PRO
Cardiol Therapeutics' Cash And Cash Equivalents Of $34.9M As Of December 31, 2023, Which Funds Operations Into 2026
Benzinga Newsdesk
Mid-Morning Market Update: Markets Mostly Lower; CVS Health Tops Q3 Views
Following the market opening Wednesday, the Dow traded down 0.31% to 35,939.39 while the NASDAQ fell 0.01% to 15,649.42. The S&P also fell, dropping 0.15% to 4,623.92.
Lisa Levin
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Shanthi Rexaline
